Clinical Presentation, Outcome, and Response to Therapy Among Patients With Acute Exacerbation of Chronic Hepatitis C

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 9, 2013, Pages 1174-1180.e11

  Sagnelli, Evangelista ^a,b   Pisaturo, Mariantonietta ^a,b   Stanzione, Maria ^a   Messina, Vincenzo ^b   Alessio, Loredana ^a   Sagnelli, Caterina ^a   Starace, Mario ^a   Pasquale, Giuseppe ^a   Coppola, Nicola ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Azienda Ospedaliera Sant'Anna e San Sebastiano di Caserta   (Italy)

Author keywords

Cirrhosis; Complication; Hepatic Flare; Response to Therapy

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC DISEASE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ITALY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RNA VIRUS; SCORING SYSTEM; TREATMENT RESPONSE; VIRUS REACTIVATION;

ALANINE AMINOTRANSFERASE; ALT; ASPARTATE AMINOTRANSFERASE; AST; CHC; CHRONIC HEPATITIS C; CIRRHOSIS; COMPLICATION; HAI; HAV; HBSAG; HCC; HCV; HDV; HEPATIC FLARE; HEPATITIS A VIRUS; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C VIRUS; HEPATITIS D VIRUS; HEPATITIS E VIRUS; HEPATOCELLULAR CARCINOMA; HEV; HISTOLOGIC ACTIVITY INDEX; IL; INTERLEUKIN; LB; LIVER BIOPSY; PEG-IFN; PEGYLATED INTERFERON; RESPONSE TO THERAPY; SUSTAINED VIROLOGIC RESPONSE; SVR;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BILIRUBIN; BIOPSY; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; ITALY; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84882779407     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.03.025     Document Type: Article

References (27)

1. Hoofnagle J.H. Hepatitis C: the clinical spectrum of disease. Hepatology 1997, 26:15S-20S.
2. Afdhal N.H. The natural history of hepatitis C. Semin Liver Dis 2004, 24:3-8.
3. Missiha S.B., Ostrowski M., Heathcote E.J. Disease progression in CHC: modifiable and nonmodifiable factors. Gastroenterology 2008, 134:1699-1714.
4. Alazawi W., Cunningham M., Dearden J., et al. Systematic review: outcome of compensated cirrhosis due to CHC infection. Aliment Pharmacol Ther 2010, 32:344-355.
5. Sheen I.S., Liaw Y.F., Lin D.Y., et al. Acute exacerbations in CHC: a clinicopathological and prognostic study. J Hepatol 1996, 24:525-531.
6. Rumi M.G., De Filippi F., Donato M.F., et al. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hepat 2002, 9:71-74.
7. Hiraga N., Suzuki F., Akuta N., et al. Clinical and virological characteristics of untreated patients with CHC who develop serum alanine aminotransferase flare-up. J Med Virol 2005, 75:240-248.
8. Sagnelli E., Coppola N., Marrocco C., et al. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol 2005, 42:646-651.
9. Rumi M.G., De Filippi F., La Vecchia C., et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005, 54:402-406.
10. Coppola N., Vatiero L.M., Sagnelli E. HCV genotype 2 as a risk factor for reactivation of chronic HCV infection. Gut 2005, 54:1207.
11. Coppola N., Pisapia R., Marrocco C., et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007, 40:110-115.
12. Coppola N., Pisapia R., Tonziello G., et al. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009, 46:222-229.
13. Sagnelli E., Imparato M., Coppola N., et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven CHC: a multicenter study. J Med Virol 2008, 80:1547-1553.
14. Coppola N., Potenza N., Pisaturo M., et al. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One 2013, 8:e65336.
15. Prati D., Gasbarrini A., Mazzotta F. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis 2010, 42:81-91. Italian Association for the Study of the Liver, Italian Society of Infectious, Tropical Diseases, Italian Society for the Study of Sexually Transmitted Diseases.
16. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264. European Association for the Study of the Liver.
17. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
18. Zampino R., Coppola N., Cirillo G., et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hep 2013, 20:517-523.
19. Sagnelli E., Stroffolini T., Mele A., et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 2005, 75:522-527.
20. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009, 119:1745-1754.
21. Sagnelli E., Argentini C., Genovese D., et al. Virological and epitope evolution of HCV infection from acute hepatitis C to subsequent episodes of HCV-related acute liver cell necrosis. Infection 2009, 37:344-348.
22. Spada E., Mele A., Berton A., et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut 2004, 53:1673-1681.
23. Thomas D.L., Thio C.L., Martin M.P., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
24. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
25. Seef L.B. Natural history of hepatitis C. Hepatology 1997, 26(Suppl 1):21S-28S.
26. Jaeckel E., Cornberg M., Wedemeyer H., et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001, 345:1452-1457.
27. Kamal S.M., Ismail A., Graham C.S., et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004, 39:1721-1731.